

INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!

https://marketpublishers.com/r/I1640D0DEBAEN.html

Date: April 2012

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: I1640D0DEBAEN

Abstracts

Incyte/ Novartis' JAKAVI (ruxolitinib, JAK 1/2 inhibitor, Registered for MF; PhII in PV/ET; JAKAFI – approved in the US) has received a positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of disease-related splenomegaly or symptoms of primary myelofibrosis (MF), post- polycythemia vera MF or post-essential thrombocythemia MF. This event triggers \$40m milestone payment from Novartis (Ex-US rights), and INCY will received a second payment of \$60m upon an achievement of reimbursement and pricing policy in specific EU countries. In FY12 guidance, these milestones were not included which ... For more details, please read our report released on April 20, 2012 on INCY, titled "Cheers for INCY - JAKAVI Receives CHMP Nod!"



Contents

COMPANIES MENTIONED

INCYTE, NOVARTIS



I would like to order

Product name: INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!

Product link: https://marketpublishers.com/r/l1640D0DEBAEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l1640D0DEBAEN.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

& Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970